Summary:
Following promising preclinical data that showcased a drug with both analgesic effects and structural benefits across joint tissues, we successfully completed a Phase 1 study to evaluate the safety and tolerability of 4P004 in osteoarthritis patients. Utilizing AI technology and insights from 11.4 million patients, we conducted an in-silico trial to identify the best responders, streamlining our participant selection for the Phase 2a Proof of Concept study. This next phase aims to demonstrate key efficacy endpoints, advancing our commitment to revolutionizing osteoarthritis treatment.
Milestone:
We are now entering Phase II of our study.
Market:
≥ 595 Millions of people have OA in the world (Kloppenburg et al., 2020). Estimated sales per year: 3-4 Milliards/year.